MindBio Therapeutics (CSE:MBIO; Frankfurt:WF6) received ethics approval for a world’s first Phase 2a take-home LSD-microdosing clinical trial in patients with major depressive disorder (MDD) in New Zealand. The...
Search results for - mindbio
MindBio Therapeutics lists on CSE
MindBio Therapeutics (CSE:MBIO) has listed its common shares on the Canadian Securities Exchange under the ticker symbol, MBIO. MindBio is the only company in the world to have clinical trials approved for LSD take-home...
